Martin A Sieber Selected Research

Nephrogenic Fibrosing Dermopathy

1/2017	Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
11/2011	Efficacy and safety of lanthanoids as X-ray contrast agents.
1/2011	The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats.
9/2010	A review of preclinical safety data for magnevist (gadopentetate dimeglumine) in the context of nephrogenic systemic fibrosis.
8/2009	Evaluating the role of zinc in the occurrence of fibrosis of the skin: a preclinical study.
6/2009	Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents.
4/2009	Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents.
10/2008	Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions.
5/2008	Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand.
1/2008	A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin A Sieber Research Topics

Disease

10	Nephrogenic Fibrosing Dermopathy 01/2017 - 01/2008
5	Body Weight (Weight, Body) 01/2017 - 01/2008
2	Fibrosis (Cirrhosis) 08/2009 - 01/2008
1	Brain Neoplasms (Brain Tumor) 01/2017
1	Dermatomycoses 05/2013
1	Superinfection 05/2013
1	Acute Kidney Injury (Acute Renal Failure) 09/2012
1	Renal Insufficiency (Renal Failure) 05/2010
1	Thrombosis (Thrombus) 12/2009
1	Vascular System Injuries 12/2009
1	Hypoxia (Hypoxemia) 02/2009

Drug/Important Bio-Agent (IBA)

9	Contrast MediaIBA 01/2017 - 01/2008
9	GadoliniumIBA 01/2017 - 01/2008
3	gadodiamide (Omniscan)FDA Link 01/2017 - 01/2008
2	LigandsIBA 01/2011 - 05/2008
2	Gadolinium DTPA (Magnevist)FDA Link 09/2010 - 01/2008
1	isoconazoleIBA 05/2013
1	imidazoleIBA 05/2013
1	Antifungal AgentsIBA 05/2013
1	Lipocalin-2IBA 09/2012
1	Plasminogen Activator Inhibitor 1IBA 09/2012
1	iodixanol (Visipaque)FDA Link 12/2011
1	iopromide (Ultravist)FDA Link 12/2011
1	ElementsIBA 11/2011
1	Lanthanoid Series Elements (Lanthanides)IBA 11/2011
1	IodineIBA 07/2010
1	Erythropoietin FDA Link 12/2009
1	ZincIBA 08/2009
1	IonsIBA 08/2009
1	Biomarkers (Surrogate Marker)IBA 02/2009
1	gadolinium EDTAIBA 01/2008

Therapy/Procedure

4	Intravenous Injections 01/2017 - 01/2008